Identification of small-animal and primate models for evaluation of vaccine candidates for human metapneumovirus (hMPV) and implications for hMPV vaccine design
- 1 June 2004
- journal article
- Published by Microbiology Society in Journal of General Virology
- Vol. 85 (6) , 1655-1663
Abstract
Human metapneumovirus (hMPV), a recently identified paramyxovirus, is the causative agent of respiratory tract disease in young children. Epidemiological studies have established the presence of hMPV in retrospective as well as current clinical samples in Europe, USA, Canada, Hong Kong and Australia. The hMPV disease incidence rate varied from 7 to 12 %. This rate of disease attack places hMPV in severity between respiratory syncytial virus and human parainfluenza virus type 3, two common respiratory pathogens of young children, the elderly and immunosuppressed individuals. To evaluate the effectiveness and safety of future hMPV antiviral drugs, therapeutic and prophylactic monoclonal antibodies (mAbs), and vaccine candidates, it was necessary to identify small-animal and primate models that efficiently supported hMPV replication in the respiratory tract and produced neutralizing serum antibodies, commonly a clinical correlate of protection in humans. In this study, various rodents (mice, cotton rats, hamsters and ferrets) and two primate species, rhesus macaques and African green monkeys (AGMs), were evaluated for hMPV replication in the respiratory tract. The results showed that hamsters, ferrets and AGMs supported hMPV replication efficiently and produced high levels of hMPV-neutralizing antibody titres. Hamsters vaccinated with subgroup A hMPV were protected from challenge with subgroup A or subgroup B hMPV, which has implications for hMPV vaccine design. Although these animal models do not mimic human hMPV disease signs, they will nevertheless be invaluable for the future evaluation of hMPV antivirals, mAbs and vaccines.Keywords
This publication has 28 references indexed in Scilit:
- Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeysJournal of General Virology, 2003
- Prevalence and Clinical Symptoms of Human Metapneumovirus Infection in Hospitalized PatientsThe Journal of Infectious Diseases, 2003
- Effects of Human Metapneumovirus and Respiratory Syncytial Virus Antigen Insertion in Two 3′ Proximal Genome Positions of Bovine/Human Parainfluenza Virus Type 3 on Virus Replication and ImmunogenicityJournal of Virology, 2003
- Human Metapneumovirus Associated with Respiratory Tract Infections in a 3-Year Study of Nasal Swabs from Infants in ItalyJournal of Clinical Microbiology, 2003
- A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infantsThe Pediatric Infectious Disease Journal, 2003
- Presence of the new human metapneumovirus in French children with bronchiolitisThe Pediatric Infectious Disease Journal, 2003
- Virological Features and Clinical Manifestations Associated with Human Metapneumovirus: A New Paramyxovirus Responsible for Acute Respiratory‐Tract Infections in All Age GroupsThe Journal of Infectious Diseases, 2002
- Characterization of Human Metapneumoviruses Isolated from Patients in North AmericaThe Journal of Infectious Diseases, 2002
- Attenuation of Bovine Parainfluenza Virus Type 3 in Nonhuman Primates and Its Ability to Confer Immunity to Human Parainfluenza Virus Type 3 ChallengeThe Journal of Infectious Diseases, 1988
- Evaluation of a Cold-Recombinant Influenza Virus Vaccine in FerretsThe Journal of Infectious Diseases, 1982